← Back to Search

Antiplatelet Agent

Antiplatelet Treatment for Ticagrelor (REVSTARTS Trial)

N/A
Waitlist Available
Research Sponsored by Hamilton Health Sciences Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy subjects
At least 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 days
Awards & highlights

REVSTARTS Trial Summary

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.

Eligible Conditions
  • Ticagrelor
  • Aspirin
  • Thrombocytopenia
  • Blood Transfusion

REVSTARTS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

REVSTARTS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reversal of platelet inhibition
Secondary outcome measures
Timing of reversal of platelet inhibition

REVSTARTS Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Antiplatelet TreatmentExperimental Treatment1 Intervention
Subjects will be treated with five days of ticagrelor in combination with acetylsalicylic acid.
Group II: ControlActive Control1 Intervention
Subjects will not receive antiplatelet treatment and their PRP will be used as the source of untreated platelets in laboratory mixing studies.

Find a Location

Who is running the clinical trial?

Hamilton Health Sciences CorporationLead Sponsor
365 Previous Clinical Trials
300,793 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Mar 2025